NYSE:CVM CEL-SCI (CVM) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free CVM Stock Alerts $1.89 +0.01 (+0.53%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$1.84▼$1.9450-Day Range$1.65▼$3.0852-Week Range$1.04▼$3.23Volume229,456 shsAverage Volume334,569 shsMarket Capitalization$102.02 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial Media Get CEL-SCI alerts: Email Address Ad DTIBuy Friday, Sell Monday, No Exceptions Every week traders grind it out Monday through Friday… But neglect trading Friday to Monday… Or… “over the weekend” As one professional trader explains, trading over the weekend is one of the most forgiving strategies you can use today. It allows him to sidestep a lot of the midweek volatility. Yet, gives him the opportunity to target some of the markets biggest stock moves. Just recently, he posted a trade on Nordstrom… The trade was published at 3pm on a Friday afternoon and by Monday morning the trade more than doubled.And for the first time in 2024, he’s sharing his strategy for free. About CEL-SCI Stock (NYSE:CVM)CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.Read More CVM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CVM Stock News HeadlinesMarch 20, 2024 | americanbankingnews.comBioCardia (NASDAQ:BCDA) & CEL-SCI (NYSE:CVM) Critical ReviewMarch 19, 2024 | stockhouse.comCEL-SCI's LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in ImmunologyMarch 28, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… March 19, 2024 | finance.yahoo.comCEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in ImmunologyMarch 11, 2024 | msn.comResearchers reveal a new mechanism that regulates intestinal stem cellsMarch 6, 2024 | businesswire.comCEL-SCI Corporation Issues Letter to ShareholdersFebruary 23, 2024 | finance.yahoo.comCVM Apr 2024 4.000 callFebruary 15, 2024 | finance.yahoo.comCEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial ResultsMarch 28, 2024 | MarketBeat (Ad)Your $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionFebruary 15, 2024 | businesswire.comCEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial ResultsFebruary 13, 2024 | finance.yahoo.comCEL-SCI Announces Closing of $7.75 Million Public Offering of Common StockFebruary 12, 2024 | seekingalpha.comCel-Sci: Fabulous Story Stock Works To Pass Muster With FDAFebruary 9, 2024 | msn.comWhy CEL-SCI Corporation (CVM) Shares Are DivingFebruary 9, 2024 | finance.yahoo.comCEL-SCI Announces Pricing of $7.75 Million Public Offering of Common StockFebruary 6, 2024 | stockhouse.comCEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer DrugJanuary 31, 2024 | stockhouse.comEuropean Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®January 8, 2024 | finance.yahoo.comCVM: Fiscal Year 2023 in ReviewDecember 22, 2023 | finance.yahoo.comCEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate DevelopmentsDecember 14, 2023 | morningstar.comCEL-SCI Corp CVMDecember 8, 2023 | finance.yahoo.comCVM: NICE To Have Your SupportDecember 4, 2023 | barrons.comUK'S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI's Multikine as Potential New Standard of Care for Head & Neck CancerNovember 20, 2023 | benzinga.comCEL-SCI Announces Closing of $5 Million Public Offering of Common StockNovember 8, 2023 | finance.yahoo.comCVM: Target Population Comes Into ReliefOctober 30, 2023 | finanznachrichten.deCEL-SCI Corporation: CEL-SCI Issues Letter to ShareholdersOctober 30, 2023 | finance.yahoo.comCEL-SCI Issues Letter to ShareholdersOctober 25, 2023 | msn.comCVM, ASTI and SONN among pre-market losersOctober 24, 2023 | finance.yahoo.comCEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory ApprovalsSee More Headlines Receive CVM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CEL-SCI and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/14/2024Today3/27/2024Next Earnings (Estimated)5/10/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNYSE:CVM CUSIPN/A CIK725363 Webcel-sci.com Phone703-506-9460Fax703-506-9471EmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,190,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-204.28% Return on Assets-95.72% Debt Debt-to-Equity Ratio0.75 Current Ratio1.26 Quick Ratio0.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.28 per share Price / Book6.75Miscellaneous Outstanding Shares53,980,000Free Float46,390,000Market Cap$102.02 million OptionableOptionable Beta1.32 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Geert R. Kersten Esq. (Age 65)Chief Executive & Financial Officer, Treasurer and Director Comp: $702.79kMs. Patricia B. Prichep (Age 73)Senior VP of Operations & Corporate Secretary Comp: $295.18kDr. Eyal Talor Ph.D. (Age 68)Chief Scientific Officer Comp: $351.88kDr. Daniel H. Zimmerman Ph.D. (Age 83)Senior Vice President of Research & Cellular Immunology Comp: $46.08kMr. John Cipriano (Age 82)Senior Vice President of Regulatory Affairs Comp: $246.97kKey CompetitorsCardiol TherapeuticsNASDAQ:CRDLIgnyte AcquisitionNASDAQ:IGNYVigil NeuroscienceNASDAQ:VIGLProtalix BioTherapeuticsNYSE:PLXZura BioNASDAQ:ZURAView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 178,478 shares on 3/11/2024Ownership: 3.853%Forthright Family Wealth Advisory LLCBought 16,500 shares on 2/28/2024Ownership: 0.031%Virtu Financial LLCBought 60,097 shares on 2/26/2024Ownership: 0.111%Cantor Fitzgerald L. P.Bought 121,000 shares on 2/15/2024Ownership: 0.241%Citadel Advisors LLCSold 3,300 shares on 2/15/2024Ownership: 0.000%View All Institutional Transactions CVM Stock Analysis - Frequently Asked Questions How have CVM shares performed in 2024? CEL-SCI's stock was trading at $2.72 at the start of the year. Since then, CVM shares have decreased by 30.5% and is now trading at $1.89. View the best growth stocks for 2024 here. When is CEL-SCI's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our CVM earnings forecast. How were CEL-SCI's earnings last quarter? CEL-SCI Co. (NYSE:CVM) announced its quarterly earnings data on Wednesday, February, 14th. The company reported ($0.14) earnings per share (EPS) for the quarter. When did CEL-SCI's stock split? Shares of CEL-SCI reverse split on Thursday, June 15th 2017. The 1-25 reverse split was announced on Monday, June 12th 2017. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 14th 2017. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. Who are CEL-SCI's major shareholders? CEL-SCI's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.15%), Vanguard Group Inc. (3.85%), D.A. Davidson & CO. (0.58%), Thoroughbred Financial Services LLC (0.25%), Cantor Fitzgerald L. P. (0.24%) and Cutter & CO Brokerage Inc. (0.17%). Insiders that own company stock include Bruno Jean-Marie Baillavoine, Eyal Talor, Geert R Kersten, John Cipriano, Peter R Young and Robert Eugene Watson. View institutional ownership trends. How do I buy shares of CEL-SCI? Shares of CVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:CVM) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThe 3rd Revolution in WarfareWeiss RatingsIs AI Energy Really 4 Million Times More Powerful Than Oil? (Surprising Answer)Banyan Hill Publishing“Cash Frenzy” to Hit Banks on March 20?Stansberry ResearchBill Ackman’s 2024 warningPorter & CompanyUrgent: Protect Your Investments from a Chinese InvasionBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CEL-SCI Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.